Management of pre-liver transplantation patient - Part 2

Liver Transplantation

Volumn 11, Issue 3, 2005, Pages 249-260

  Sharma, Pratima ^a   Rakela, Jorge ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMPICILLIN; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CEFOTAXIME; COLESTYRAMINE; DILTIAZEM; DIURETIC AGENT; FLUMAZENIL; FUROSEMIDE; LIXIVAPTAN; MAGNESIUM; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OFLOXACIN; PROSTACYCLIN; PROSTAGLANDIN INHIBITOR; QUININE SULFATE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SPIRONOLACTONE; TERLIPRESSIN; TOBRAMYCIN; UNINDEXED DRUG; VAPREOTIDE; VASOACTIVE AGENT; VASOPRESSIN; ZINC;

ACUTE DISEASE; ASCITES; BLEEDING; BLOATING; BRAIN ISCHEMIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; ENDOSCOPIC THERAPY; ESOPHAGUS VARICES BLEEDING; GYNECOMASTIA; HEART ARRHYTHMIA; HEART INFARCTION; HEPATIC ENCEPHALOPATHY; HEPATOPULMONARY SYNDROME; HUMAN; HYDROTHORAX; HYPONATREMIA; IMPOTENCE; INTENSIVE CARE; INTESTINE ISCHEMIA; KIDNEY FAILURE; LIBIDO DISORDER; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; META ANALYSIS; MORBIDITY; MORTALITY; MUSCLE CRAMP; OSTEOPENIA; OSTEOPOROSIS; OTOTOXICITY; PERIPHERAL NEUROPATHY; PERITONITIS; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; REVIEW; SCLEROTHERAPY; STOMACH VARICES; TISSUE NECROSIS; TREATMENT CONTRAINDICATION;

ASCITES; BACTERIAL INFECTIONS; ESOPHAGEAL AND GASTRIC VARICES; HEPATIC ENCEPHALOPATHY; HUMANS; HYDROTHORAX; HYPERTENSION, PULMONARY; KIDNEY FAILURE; LIVER TRANSPLANTATION; PERITONITIS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE;

EID: 16244372421     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20379     Document Type: Review

References (100)

1. Roberts LR, Kamath PS. Pathophysiology and treatment of variceal hemorrhage. Mayo Clin Proc 1996;71:973-983.
2. McCormick PA, O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut 2001;49: 682-685.
3. Beppu K, Inokuchi K, Koyanagi N, Nakayama S, Sakata H, Kitano S, Kobayashi M. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981;27:213-218.
4. D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997;11:243-256.
5. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988;95: 1351-1355.
6. Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991;36:1204-1208.
7. Vargas HE, Gerber D, Abu-Elmagd K. Management of portal hypertension-related bleeding. Surg Clin North Am 1999;79: 1-22.
8. Feu F, Bordas JM, Luca A, Garcia-Pagan JC, Escorsell A, Bosch J, Rodes J. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology 1993;18:1082-1089.
9. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991;324:1532-1538.
10. Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986;6:101-106.
11. Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991;114:869-873.
12. Fardy JM, Laupacis A. A meta-analysis of prophylactic endoscopic sclerotherapy for esophageal varices. Am J Gastroenterol 1994;89:1938-1948.
13. Paquet KJ, Kalk JF, Klein CP, Gad HA. Prophylactic sclerotherapy for esophageal varices in high-risk cirrhotic patients selected by endoscopic and hemodynamic criteria: a randomized, single-center controlled trial. Endoscopy 1994;26:734-740.
14. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-354.
15. Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999;340:988-993.
16. Schepke M, Kleber G, Nurnberg D, Willert J, Koch L, Veltzke-Schlieker W, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004; 40:65-72.
17. Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt. Semin Liver Dis 1999;19:457-473.
18. Rosado B, Kamath PS. Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl 2003;9:207-217.
19. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505.
20. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:1655-1661.
21. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000;33:846-852.
22. Bosch J, Lebrec D, Jenkins SA. Development of analogues: successes and failures. Scand J Gastroenterol Suppl 1998;226: 3-13.
23. Cales P, Masliah C, Bernard B, Garnier PP, Silvain C, Szostak-Talbodec N, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension. N Engl J Med 2001;344:23-28.
24. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995;333:555-560.
25. de Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 1999;19:439-455.
26. Henderson JM, Boyer TD, Kutner MH, Rikkers LF, Jeffers L, Abu-Elmagd K. Distal splenorenal shunt versus transjugular intrahepatic portosystemic shunt: a prospective randomized controlled trial. Hepatology 2004;40:725A.
27. Runyon BA. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986;146:2259-2261.
28. Bobadilla M, Sifuentes J, Garcia-Tsao G. Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis. J Clin Microbiol 1989;27:2145-2147.
29. Castellote J, Xiol X, Verdaguer R, Ribes J, Guardiola J, Gimenez A, Casais L. Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous bacterial peritonitis. Am J Gastroenterol 1990;85:1605-1608.
30. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841-856.
31. Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol 1981; 3(Suppl 1):73-80.
32. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-810.
33. Abbasoglu O, Goldstein RM, Vodapally MS, Jennings LW, Levy MF, Husberg BS, Klintmalm GB. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin Transplant 1998;12:263-269.
34. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-939.
35. Perez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983;84:961-968.
36. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176.
37. Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. N Engl J Med 1989;321:1632-1638.
38. Gines P, Arroyo V, Vargas V, Planas R, Casafont F, Panes J, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991;325:829-835.
39. Stanley MM, Reyes CV, Greenlee HB, Nemchausky B, Reinhardt GF. Peritoneal fibrosis in cirrhotics treated with peritoneovenous shunting for ascites. An autopsy study with clinical correlations. Dig Dis Sci 1996;41:571-577.
40. Ochs A, Rossle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995;332:1192-1197.
41. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003;124: 634-641.
42. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-1707.
43. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004;40:629-635.
44. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-1847.
45. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996;25:135-144.
46. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142-153.
47. Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, Rodes J. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985;5:457-462.
48. Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991;100: 1737-1742.
49. Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996;111:1011-1017.
50. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001; 120:726-748.
51. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-1976.
52. Norenberg MD. Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 1996;16:245-253.
53. Blei AT. Hepatic encephalopathy in the age of TIPS. Hepatology 1994;20:249-252.
54. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999; 29:648-653.
55. Riggio O, Merli M, Capocaccia L, Caschera M, Zullo A, Pinto G, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992;16:785-789.
56. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996;23:1084-1092.
57. Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991;100:1114-1118.
58. Brown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut 1974;15:999-1004.
59. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002;8:433-439.
60. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997;25:1351-1360.
61. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992; 16:138-144.
62. Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis 1996;16:329-338.
63. Gyr K, Meier R, Haussler J, Bouletreau P, Fleig WE, Gatta A, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996; 39:319-324.
64. van der Giet M, Schmidt S, Tolle M, Jankowski J, Schluter H, Zidek W, Tepel M. Effects of dinucleoside polyphosphates on regulation of coronary vascular tone. Eur J Pharmacol 2002; 448:207-213.
65. Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-1502.
66. Arroyo V, Fernandez-Esparrach G, Gines P. Diagnostic approach to the cirrhotic patient with ascites. J Hepatol 1996; 25(Suppl 1):35-40.
67. Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-1153.
68. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229-236.
69. Bataller R, Gines P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997;17:233-247.
70. Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002;17:739-747.
71. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-380.
72. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29:1690-1697.
73. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-295.
74. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS to selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.
75. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-286.
76. Martinez GP, Barbera JA, Visa J, Rimola A, Pare JC, Roca J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 2001;34:651-657.
77. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995;122:521-529.
78. Battaglia SE, Pretto JJ, Irving LB, Jones RM, Angus PW. Resolution of gas exchange abnormalities and intrapulmonary shunting following liver transplantation. Hepatology 1997;25: 1228-1232.
79. Abrams GA, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995;109:1283-1288.
80. Krowka MJ. Hepatopulmonary syndromes. Gut 2000;46:1-4.
81. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1166.
82. Corley DA, Scharschmidt B, Bass N, Somberg K, Gold W, Sonnenberg K. Lack of efficacy of TIPS for hepatopulmonary syndrome. Gastroenterology 1997;113:728-730.
83. Poterucha JJ, Krowka MJ, Dickson ER, Cortese DA, Stanson AW, Krom RA. Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology 1995;21:96-100.
84. Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med 1998;158: 643-661.
85. Krowka MJ, Porayko MK, Plevak DJ, Pappas SC, Steers JL, Krom RA, Wiesner RH. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 1997; 72:44-53.
86. Krowka M. Hepatopulmonary syndrome and liver transplantation. Liver Transpl 2000;6:113-115.
87. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
88. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997;63:604-606.
89. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648.
90. Alberts WM, Salem AJ, Solomon DA, Boyce G. Hepatic hydrothorax. Cause and management. Arch Intern Med 1991; 151:2383-2388.
91. Gordon FD, Anastopoulos HT, Crenshaw W, Gilchrist B, McEniff N, Falchuk KR, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997;25:1366-1369.
92. Ferrante D, Arguedas MR, Cerfolio RJ, Collins BG, van Leeuwen DJ. Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax. Am J Gastroenterol 2002;97:3172-3175.
93. Javitt NB. Timing of cholestyramine doses in cholestatic liver disease. [Letter]. N Engl J Med 1974;290:1328-1329.
94. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988;94:488-493.
95. Bergasa NV, Jones EA. Management of the pruritus of cholestasis: potential role of opiate antagonists. Am J Gastroenterol 1991;86:1404-1412.
96. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997;113:1264-1269.
97. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Munch JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998;28:695-699.
98. Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996;11:417-421.
99. Van Berkum FN, Beukers R, Birkenhager JC, Kooij PP, Schalm SW, Pols HA. Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids. Gastroenterology 1990;99:1134-1139.
100. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002;50(Suppl 1):i1-i9.